logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
08/11/2025
Taliban spokesperson: We have not violated the ceasefire agreement reached so far, and we will continue to abide by it.
Latest
3 m ago
The Hong Kong Special Administrative Region will send the largest delegation ever to the National Games.
7 m ago
Yangjie Technology: Currently the overall prices of the company's products are stable.
9 m ago
National Radio and Television Administration: Launching Special Governance for Bad Animation Micro-Series and Animation Short Videos.
14 m ago
When conducting research in Guizhou, Chen Wenqing stated that we must thoroughly study and implement the spirit of the Fourth Plenary Session of the 20th CPC Central Committee, and work hard to build a higher level of law-based China with stability.
21 m ago
After competing with Norvatis and Novartis for the acquisition of a startup company focused on weight loss medications, Pfizer has finalized the acquisition of Metsera for $10 billion. Norvatis and Novartis have stated that after careful evaluation, they have decided not to increase their acquisition offer and will continue to focus on business expansion and other acquisition opportunities. According to the agreement, Pfizer will complete the transaction at a price of up to $86.25 per share, including an initial cash payment of $65.60 per share and an additional consideration of up to $20.65 per share if certain performance targets are met.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.